Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Christopher Mitchell

Physician Assistant Mayfield Heights, OH Physician Assistant

NPI 1972583375 CMS profile 1017497

5915 Landerbrook Dr, Ste. 110, Mayfield Heights, OH 44124

Open in the dashboard

General payments

$9,688

440 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Mitchell of Mayfield Heights, OH is reported in the CMS Open Payments database as having received $9,688 across 440 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,655 172
2024 General $3,151 141
2023 General $2,365 107
2022 General $517 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Mitchell
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Christopher Mitchell were reported at $3,655. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Christopher Mitchell Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $517 $155 $48–$522 $149
2023 $2,365 $167 $52–$557 $160
2024 $3,151 $178 $55–$600 $164
2025 $3,655 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. GlaxoSmithKline, LLC. $1,658 93 payments
  2. AstraZeneca Pharmaceuticals LP $1,654 66 payments
  3. Regeneron Healthcare Solutions, Inc. $879 35 payments
  4. CSL Behring $850 41 payments
  5. Genzyme Corporation $834 32 payments
  6. Amgen Inc. $661 32 payments
  7. Novartis Pharmaceuticals Corporation $402 17 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $321 13 payments
  9. Pfizer Inc. $319 14 payments
  10. Genentech USA, Inc. $237 11 payments
  11. Other $1,872 86 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $9,491 434 payments
  2. Education $197 6 payments
Products named General payments · program years 2022–2025
  1. DUPIXENT Immunology $1,342 52 payments
  2. NUCALA $952 61 payments
  3. TEZSPIRE Respiratory $794 20 payments
  4. DUPIXENT Inflammation And Immunology $686 28 payments
  5. TEZSPIRE Inflammation $625 30 payments
  6. Hizentra $586 31 payments
  7. TRELEGY ELLIPTA $499 30 payments
  8. AIRSUPRA $472 19 payments
  9. FASENRA $384 16 payments
  10. CUTAQUIG $284 12 payments
  11. Other $4,098 183 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

471

Median for Physician Assistant: 241

Drug cost

$41,554

Median for Physician Assistant: $4,110

Branded share of claims

31.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 42 $27,585
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 31 $6,437
Wixela Inhub Fluticasone Propion/Salmeterol Brand 22 $2,480
Albuterol Sulfate Hfa Albuterol Sulfate Brand 38 $1,119
Azelastine Hcl Generic 38 $829
Clarithromycin Generic 12 $524
Ipratropium Bromide Generic 20 $431
Famotidine Generic 34 $339
Doxycycline Hyclate Generic 32 $279
Montelukast Sodium Generic 60 $257

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$681,847

Of which drugs: $653,836

Medicare patients

131

Average age 72

Services billed

20,125

90 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 58%
Depression 31%
COPD 30%
Diabetes 27%
Ischemic heart disease 25%
Osteoporosis 24%
Chronic kidney disease 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 15 8,130 $243,007

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $392
  • GENZYME CORPORATION $216
$608 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $229
  • Amgen Inc. $190
$419 — —
NUCALA
  • GlaxoSmithKline, LLC. $333
$333 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $136
  • Genentech USA, Inc. $89
$225 — 8,130
Hizentra
  • CSL Behring $212
$212 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

440 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record